With the pharmaceutical industry’s focus on oncology and more targeted therapies, the number of highly potent active pharmaceutical ingredients (HPAPIs) in development continues to increase. as does the demand for HPAPI manufacturing capacity. As described in this technical brief, Lonza has more than 20 years’ experience in the manufacture and handling of HPAPIs. Our expertise, capabilities, manufacturing innovation, and integrated service options are described. To learn more, please read our technical brief.